ValiRx plc

Equities

VAL

GB00BLH13C52

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:15 2024-05-31 am EDT			5-day change	1st Jan Change
2.95 ^GBX	-.--%		+2.43%	-50.00%

May. 20	London gets boost thanks to rate cut hopes	AN
May. 20	ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant	AN

ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant

May 20, 2024 at 09:22 am EDT

(Alliance News) - ValiRx PLC on Monday noted that the peptide nanoparticle formation Cytolytix received a Knowledge Transfer Voucher grant in conjunction with The Open University.

The life sciences company focused on early-stage cancer therapeutics and women's health highlighted that the assessment of formulation options for the triple negative breast cancer project CLX001 has progressed during the first quarter of 2024.

Cytolytix Ltd is a partially-owned ValiRx subsidiary established to progress CLX001.

"This initial grant is being used in a pilot study to assess the effectiveness of Cytolytix's cancer-specific lytic peptides in neuroendocrine prostate cancer," ValiRx said.

Meanwhile, ValiRx noted that the number of prospective clients for Inaphaea BioLabs's services is continuing to grow, with 11 at an advanced stage of discussion.

ValiRx shares jumped 31% to 2.88 pence each on Monday afternoon in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Latest news about ValiRx plc

London gets boost thanks to rate cut hopes	May. 20	AN
ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant	May. 20	AN
ValiRx plc Provides an Operational Update	May. 20	CI
EARNINGS AND TRADING: Tullow Oil on track to hit free cash flow target	May. 16	AN
Vertu Motors ups dividend as hails record revenue	May. 15	AN
AIM WINNERS & LOSERS: Itim up on Majestic Wine contract renewal	May. 15	AN
ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2023	May. 15	CI
Valirx plc Reiterates Earnings Guidance for the Year 2024	Apr. 24	CI
Valirx plc Announces Directorate Changes	Apr. 22	CI
ValiRx inks evaluation deal with Imperial College London for research	Mar. 21	AN
ValiRx plc Announces Signature of an Evaluation Agreement with Imperial College London	Mar. 21	CI
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	Mar. 19	AN
ValiRx Kick off Search for New CEO	Mar. 19	MT
Valirx plc Announces Board Appointments, Subject to Completion of Regulatory Due Diligence	Mar. 19	CI
EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout	Feb. 29	AN
Valirx plc Intends to Appoint Martin Gouldstone as Non-Executive Director	Feb. 29	CI
ValiRx Says Shareholder Group's Requisition Notice Invalid	Feb. 13	MT
ValiRx says requisition notice from shareholder group is invalid	Feb. 13	AN
ValiRx signs research sharing deal with Dundee University	Feb. 12	AN
Valirx Signs Research, Evaluation Agreements with University of Dundee	Feb. 12	MT
ValiRx plc Announces Agreement with Dundee Uni and Project Initiation	Feb. 12	CI
ValiRx receives shareholder request for board change	Feb. 09	AN
ValiRx plc Announces Resignation of Stella Panu as A Non-Executive Director, Effective from 15 April 2024	Jan. 18	CI
ValiRx raises GBP192,200, part of wider GBP1.8 million raise	Dec. 19	AN
Good Energy says ZapMap expands into mainland Europe	Dec. 13	AN

Chart ValiRx plc

Duration

Period

More charts

Company Profile

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

Sector

Biotechnology & Medical Research

Calendar

08:00am - Shareholders Meeting - Q&A

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALIRX PLC	-50.00%	4.97M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs